- 関
- 13!I-tositumomab
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma.
- Jacene H1,2, Crandall J3,4, Kasamon YL5, Ambinder RF5, Piantadosi S6, Serena D3, Kasecamp W3, Wahl RL3,5,4.
- Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.Mol Imaging Biol.2016 Oct 31. [Epub ahead of print]
- PURPOSE: To determine the maximum tolerated dose (MTD) of [131I]tositumomab in patients with refractory/recurrent Hodgkin lymphoma (HL) and to preliminarily determine if [131I]tositumomab has activity against HL and if positron emission tomography (PET) with 2-deoxy-2-[18F]fluoro-D-glucose ([18F]DG)
- PMID 27798787
- CHOP Chemotherapy Followed by Tositumomab and Iodine-131 Tositumomab for Previously Untreated Diffuse Large B-cell Lymphoma.
- Leonard JP1, Gregory SA2, Smith H3, Horner TJ4, Williams VC5, Giampietro P4, Lin TS6.
- Clinical lymphoma, myeloma & leukemia.Clin Lymphoma Myeloma Leuk.2016 Apr;16(4):191-6. doi: 10.1016/j.clml.2015.12.011. Epub 2016 Jan 4.
- The efficacy and safety of tositumomab/iodine-131 tositumomab (TST/I-131 TST) were evaluated in diffuse large B-cell lymphoma patients who responded to first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Fifteen patients (median age, 52 years) received dosimetric and therap
- PMID 26832194
- Radioimmunotherapy and Autologous Stem-Cell Transplantation in the Treatment of B-Cell Non-Hodgkin Lymphoma.
- Shimoni A1, Zwas ST2.
- Seminars in nuclear medicine.Semin Nucl Med.2016 Mar;46(2):119-25. doi: 10.1053/j.semnuclmed.2015.10.009.
- High-dose chemotherapy and autologous stem-cell transplantation (ASCT) is the standard therapy for patients with chemosensitive-relapsed or chemosensitive-refractory aggressive lymphoma. The use of rituximab, an anti-CD20 monoclonal antibody, has dramatically changed the outcome of patients with agg
- PMID 26897716
Japanese Journal
- Radioimmunotherapy(RIT)によるB細胞性リンパ腫治療の展望--Ibritumomab tiuxetan(Zevalin)とtositumomab(Bexxar) (第1土曜特集 造血器腫瘍の分子標的療法) -- (期待される分子標的療法とその臨床効果)
- 濾胞性リンパ腫患者に対する初期治療としての131I-tositumomab(Bexxar)によるradioimmunotherapy
- Radioimmunotherapy--131Iあるいは90Yを抱合したマウス型抗CD20抗体によるB細胞リンパ腫の治療 (第1土曜特集 造血器腫瘍のあらたな治療戦略) -- (新しい治療戦略のトピックス)
Related Links
- Secondary Malignancies: Hematological and non-hematological secondary malignancies have been reported. (5.4) • Hypothyroidism: Thyroid-blocking medication is required prior to administration of the BEXXAR therapeutic regimen.
- Bexxar is used to treat certain forms of non-Hodgkin lymphoma. Learn about side effects, interactions and indications. ... Bexxar side effects Serious and sometimes fatal allergic reactions may occur during treatment with Bexxar. ...
Related Pictures